SEC EDGAR: Layoffs & Restructuring

TrueBlue Q4 2025 Earnings Release

TrueBlue announced its fourth quarter and full-year 2025 financial results, reporting revenue of $418 million and a net loss of $32 million for the quarter. The company highlighted organic revenue growth and strategic cost-saving measures, with a focus on improving profitability and building a more efficient organization for sustainable growth.

Akamai Technologies Q4 and Full-Year 2025 Financial Results

Akamai Technologies reported its fourth quarter and full-year 2025 financial results, announcing $1.095 billion in Q4 revenue and $4.208 billion for the full year. The company also disclosed a $55 million restructuring charge, impacting GAAP net income per diluted share.

BioAtla Reports 70% Workforce Reduction and Severance Costs

BioAtla, Inc. has announced a significant workforce reduction of approximately 70%, with actions committed on February 24, 2026. The company estimates severance costs associated with this reduction to be between $0.5 million and $0.6 million. This filing is a Current Report on Form 8-K.

Korro Bio Reports Q4 FY25 Results, Restructuring, and Workforce Reductions

Korro Bio reported its Q4 and full-year 2025 financial results, announcing a corporate restructuring and workforce reduction. The company also provided an update on its drug development pipeline, including nominating a new candidate for hyperammonemia treatment and advancing another for alpha-1 antitrypsin deficiency. An $85 million private placement is expected to extend the company's cash runway into late 2028.

Bicycle Therapeutics Announces Workforce Reduction and Financial Results

Bicycle Therapeutics announced a proposed workforce reduction of approximately 30% as part of a strategic reprioritization. This action is expected to extend the company's cash runway into 2030. The company also reported its fourth quarter and full year 2025 financial results.